Indonesia Healthcare (Pharma and Medical Devices) Market Analysis, Regulatory, Reimbursement and Competitive Landscape

1.1 List of Figures
1.2 List of Tables

2.1 Executive Summary
2.2 Key Highlights: Facts About the Indonesian Healthcare Market
2.3 Key Highlights: Healthcare Startups in Indonesia
2.4 Key Events: Indonesian Healthcare Timeline, 2016-22
2.5 Key Events: Indonesian Pharmaceutical Market
2.6 Key Events: M&As, VC & PE Deals, Global Pharmaceutical Market, 2021-22
2.7 Key Events: Mergers and Acquisitions
2.8 Country Profile, Indonesia, 2021

3.1 Pharmaceutical Market - Overview
3.2 Pharmaceutical Market - Exports
3.3 Pharmaceutical Market - Imports
3.4 Pharmaceutical Market - Supply Channels, Indonesia
3.5 Pharmaceutical Market - Market Segments
3.6 Pharmaceutical Market - Market Segments, Generics, Indonesia
3.7 Pharmaceutical Market - Market Segments, Biologics and Biosimilars, Indonesia
3.8 Pharmaceutical Market - Market Segment, Halal Drugs, Indonesia
3.9 Pharmaceutical Market - Market Segment, Traditional Medicines, Indonesia
3.10 Pharmaceutical Market - Market Segment, Over-the-Counter Medicines, Indonesia
3.11 COVID-19 Epidemiology, Indonesia
3.12 COVID-19 Impact and Developments in the Healthcare Market, Indonesia
3.13 COVID-19 Clinical Trials Landscape, Indonesia
3.14 Pharmaceutical Market - Major Players

4.1 Medical Device Market - Overview
4.2 Medical Devices Market - Major Players

5.1 Drivers
5.2 Barriers

6.1 Deal Analysis: Pharmaceutical Market, Indonesia, 2020-22
6.2 Deal Analysis: Medical Device Market, Indonesia, 2020-22

7.1 Healthtech Landscape, Indonesia
7.2 Healthtech Deals Landscape, Indonesia
7.3 Key Healthtech Deals, Indonesia
7.4 Adoption of Technology in Healthcare, Indonesia
7.5 Digital Healthcare Regulations, Indonesia
7.6 Healthtech Landscape: Benefits and Risks, Indonesia
8. Market Access
8.1 Overview of Healthcare System, Indonesia
8.2 Reimbursement Landscape, Indonesia
8.3 Overview of Insurance Providers, Public Insurance, Indonesia
8.4 Overview of Insurance Providers, Private Insurance, Indonesia
8.5 Healthcare Spending and Prescription Drug Price Trend, Indonesia
8.6 Pricing Policies, Indonesia
8.7 Market Access Timeline, Indonesia, 2013-21
8.8 Regulatory Landscape, Indonesia
8.8.1 Marketing Authorization for Pharmaceutical Products, Indonesia
8.8.2 Marketing Authorization for Medical Devices, Indonesia
8.8.3 Intellectual Property Rights, Patents, Indonesia
8.8.4 Intellectual Property Rights, Trademark, Indonesia
8.8.5 Clinical Trial Regulation Process, Indonesia
8.8.6 Pharmaceutical Clinical Trials Landscape, Indonesia
8.8.7 Pharmaceutical Import and Export, Indonesia
8.8.8 Pharmaceutical Advertising Regulations, Indonesia
8.8.9 Labeling and Packaging Regulations, Indonesia

9.1 Indonesian Healthcare Policy Highlights
9.2 Healthcare Facilities and Healthcare Resources, Indonesia
9.3 Life Expectancy and Immunization Rate, Indonesia
9.4 Environmental Health, Indonesia
9.5 Healthcare Personnel, Indonesia
9.6 Disease Burden, Indonesia
9.7 Healthcare Expenditure, Indonesia

13.1 Research Methodology
13.1.1 Coverage
13.1.2 Secondary Research
13.1.3 Forecasts
13.2 Bibliography
13.3 About the Publisher
13.4 Contact the Publisher
13.5 Disclaimer

Table 1: Phase-wise development plan as per the RIPIN, Indonesia, 2022
Table 2: Development plan of biotechnological products and vaccines, Indonesia, 2022
Table 3: COVID-19 indicators (number of cases), Global and Indonesia, 2022
Table 4: COVID-19-related travel restrictions, Indonesia, 2020-22
Table 5: Marketed COVID-19 IVD products, Indonesia, 2021-22
Table 6: Pipeline COVID-19 IVD products, Indonesia, 2021-22
Table 7: Phase-wise development of medical device industry as per the RIPIN, Indonesia, 2022
Table 8: HET for COVID-19 therapeutic drugs, Indonesia, 2021
Table 9: Difference between the OSS and OSS RBA, Indonesia, 2022
Table 10: Drug registration fees, Indonesia, 2022
Table 11: Medical device authorization fees, Indonesia, 2022
Table 12: Patent approval fees, Indonesia, 2022
Table 13: Trademark approval fees, Indonesia, 2022
Table 14: Summary of product characteristics, Indonesia, 2022
Table 15: Pharmaceutical label, Indonesia, 2022
Table 16: Trade fairs, Indonesia, 2022-23

Figure 1: Pharmaceutical market, revenue ($B), Indonesia, 2012-21
Figure 2: Medical devices market, revenue ($B), Indonesia, 2019-26
Figure 3: Healthcare start-ups in Indonesia, 2022
Figure 4: Country profile, Indonesia, 2021
Figure 5: Pharmaceutical market, revenue ($B), Indonesia, 2012-21
Figure 6: Pharmaceutical market, revenue forecast ($B), Indonesia, 2022-27
Figure 7: Stages of RIPIN, Indonesia, 2022
Figure 8: Pharmaceutical exports ($M), Indonesia, 2014-21
Figure 9: Top export partners, Indonesia, 2021
Figure 10: Pharmaceutical imports ($M), Indonesia, 2014-21
Figure 11: Top import partners, Indonesia, 2021
Figure 12: Pharmaceutical supply channel, Indonesia, 2022
Figure 13: Arrangements of CDOB, Indonesia, 2022
Figure 14: Illustration of service flow and drug supply chain data from producers to primary healthcare facilities, Indonesia, 2022
Figure 15: Proposed solutions on the problems, Indonesia, 2022
Figure 16: Pharmaceutical companies listed on Indonesia Stock Exchange, 2021
Figure 17: Biosimilar market, revenue ($M), Indonesia, 2012-21
Figure 18: OTC market revenue ($B), Indonesia, 2013-21
Figure 19: OTC medicines market ($M), major distribution channels, Indonesia, 2021
Figure 20: OTC medicines market ($M), major categories, Indonesia, 2021
Figure 21: COVID-19 cases, Indonesia, 2020-22
Figure 22: COVID-19 deaths, Indonesia, 2020-22
Figure 23: COVID-19 stringency index (based on the share of people who are non vaccinated), Indonesia, 2020-22
Figure 24: COVID-19 containment and health index, Indonesia, 2020-22
Figure 25: COVID-19 fiscal stimulus timeline, Indonesia, 2020
Figure 26: COVID-19 approved vaccines, Indonesia, 2022
Figure 27: COVID-19 vaccination plan, Indonesia, 2022
Figure 28: COVID-19 vaccine distribution, Indonesia, 2022
Figure 29: COVID-19 clinical trials count by trial status, Indonesia, 2021-22
Figure 30: COVID-19 clinical trials count by trial phase, Indonesia, 2021-22
Figure 31: Top COVID-19 clinical trials sponsors by trial count, Indonesia, 2021-22
Figure 32: Medical devices market, revenue ($B), Indonesia, 2019-26
Figure 33: Medical devices market, revenue ($B) of major companies, Indonesia, 2020
Figure 34: Deal value and deal count, pharmaceutical market, Indonesia, 2020-22
Figure 35: Top therapy areas by deal count, pharmaceutical market, Indonesia, 2020-22
Figure 36: Deal value and deal count subtypes, pharmaceutical market, Indonesia, 2020-22
Figure 37: Deal value and deal count, medical devices market, Indonesia, 2020-22
Figure 38: Deal value and deal count subtypes, medical devices market, Indonesia, 2020-22
Figure 39: Deal value and deal count, quarterly, medical devices market, Indonesia, 2020-22
Figure 40: Top equipment sectors by deal value ($M), medical devices market, Indonesia, 2020-22
Figure 41: Top equipment sectors by deal count, medical devices market, Indonesia, 2020-22
Figure 42: M&A deals by quarter, medical devices market, Indonesia, 2020-22 (by value and by number)
Figure 43: VC deals by quarter, medical devices market, Indonesia, 2020-22 (by value and by number)
Figure 44: Programs for development of healthtech ecosystem, Indonesia, 2022
Figure 45: Deal value ($B) and deal count, Healthtech, Indonesia, 2020-22
Figure 46: Deal values ($B) and deal count by sector, Healthtech, Indonesia, 2020-22
Figure 47: Missions of Digital Transformation Program, Healthtech, Indonesia, 2022
Figure 48: Priority activity of blueprint for digital health transformation, Healthtech, Indonesia, 2022
Figure 49: Roadmap of health technology transformation, Healthtech, Indonesia, 2022
Figure 50: Telemedicine service flow as per the blueprint for the digital transformation, Healthtech, Indonesia, 2022
Figure 51: Overview of healthcare system, Indonesia, 2022
Figure 52: Total insured population and insurance per 1,000 residents, Indonesia, 2014-18
Figure 53: Indonesian residents without any insurance coverage, 2019
Figure 54: OOP expenditure (% of total expenditure on health), Indonesia, 2013-22
Figure 55: Annual rate of change (%), health price index, Indonesia, 2012-19
Figure 56: Organization of BPOM, Indonesia, 2022
Figure 57: Drug registration process, Indonesia, 2022
Figure 58: Traditional drug registration process, Indonesia, 2022
Figure 59: Halal drug registration process, Indonesia, 2022
Figure 60: Medical device classification as per the risk for patients, Indonesia, 2022
Figure 61: In vitro medical device classification as per the risk for individual and community, Indonesia, 2022
Figure 62: Medical device registration process, Indonesia, 2022
Figure 63: Organizational structure of DGIP, Indonesia, 2022
Figure 64: Patent approval process, Indonesia, 2022
Figure 65: Trademark registration process, Indonesia, 2022
Figure 66: Pre-marketing clinical trial approval, Indonesia, 2022
Figure 67: Post-marketing clinical trial approval, Indonesia, 2022
Figure 68: Pharmaceutical clinical trials count by trial status, Indonesia, 2021-22
Figure 69: Top five pharmaceutical clinical trials count by indication, Indonesia, 2021-22
Figure 70: Pharmaceutical clinical trials count by phase, Indonesia, 2021-22
Figure 71: Top four pharmaceutical clinical trials sponsors by count, Indonesia, 2021-22
Figure 72: Essential labeling requirements of medical devices, Indonesia, 2022
Figure 73: Missions of RPJMN, Indonesia, 2022
Figure 74: Indonesia Vision 2045
Figure 75: Strategies of eradicating caries, Indonesia, 2022
Figure 76: Number of hospitals, Indonesia, 2016-22
Figure 77: Number of hospitals by class, Indonesia, 2020
Figure 78: Hospital beds (per 1,000 population), Indonesia, 2015-22
Figure 79: Life expectancy at birth (years), Indonesia, 2013-22
Figure 80: Immunization rate (%), Indonesia, 2013-21
Figure 81: PM2.5 (µg per m3), Indonesia, 2013-22
Figure 82: CO2 emissions (metric tons per capita), Indonesia, 2013-22
Figure 83: Physicians (per 10,000 population), Indonesia, 2015-21
Figure 84: Pharmacists (per 10,000 population), Indonesia, 2015-21
Figure 85: Dentists (per 10,000 population), Indonesia, 2015-21
Figure 86: Nurses (per 10,000 population), Indonesia, 2015-21
Figure 87: Major causes of mortality (per 100,000 population), Indonesia, 2019
Figure 88: Major causes of male mortality (per 100,000 population), Indonesia, 2019
Figure 89: Major causes of female mortality (per 100,000 population), Indonesia, 2019
Figure 90: DALYs by major disease (per 100,000 population), Indonesia, 2019
Figure 91: Healthcare expenditure as a percentage of GDP (%), Indonesia, 2013-22
Figure 92: Health expenditure share (% of total health spending), Indonesia, 2013-22